Oslo, Norway, 26 March 2021: Reference is made to the stock exchange release by
Photocure ASA ("Photocure" or the "Company") published on 25 March 2021
regarding exercise of share options.

The price for option shares sold by primary insiders have been determined at a
price of NOK 130.6672 per share.

The primary insiders having exercised options have used the net proceeds from
the sale of option shares to purchase shares in Photocure at a price per share
of NOK 130.6672 as follows:

  · Dan Schneider, CEO, has purchased 17,980 shares.
  · Erik Dahl, CFO, has purchased 3,236 shares.
  · Geoffrey Coy, VP and General Manager of U.S. Operations, has purchased 8,081
shares.
  · Grete Hogstad, VP Global Strategic Marketing & Business Development, has
purchased 1,872 shares.
  · Kari Myren, VP Global Medical Affairs and Clinical Development, has
purchased 1,872 shares.

The shares are purchased at the stated price from Photocure's holding of own
shares. Following the transaction Photocure will hold 15,666 own shares.

Primary insider notifications pursuant to the market abuse regulation article 19
are attached.

For further information, please contact:

Photocure
CFO Erik Dahl
Tel: +47 450 55 000
Email: ed@photocure.com

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com or www.cysview.com

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA.

This information is subject to the disclosure requirements pursuant to the
market abuse regulation article 19 and 5-12 of the Norwegian Securities Trading
Act.